Approval · Notice of Compliance 37421 · 2026
VENCLEXTA: Notice of Compliance 37421
Issued April 28, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37421
- Date
- April 28, 2026
- Company
- AbbVie CorporationSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of new indication: VENCLEXTA, in combination with ibrutinib, is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL).
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VENCLEXTA | Not yet assigned | — |
Medicinal ingredients
- VENETOCLAX 10 MG per TAB
- VENETOCLAX 50 MG per TAB
- VENETOCLAX 100 MG per TAB